

101005177 — COVID-RED

COVID-RED

**WP2 – Testing procedure and
implementation**

D2.2 Interim report on testing results for SARS-CoV-2 virus

Lead contributor	8. Roche Diagnostics Nederland BV
Other contributors	3. Julius Clinical 6. Sanquin 9. LMZ Dr. Risch

Document History

Version	Date	Description
V1.0	08-10-2021	Deliverable developed for internal review prior to finalization
V1.1	26-11-2021	Table 1 updated after consortium comment

Intermediate testing report.

Based on the procedures established in deliverable 2.1 we are providing the following intermediate testing report. Please see in table 1 the current figures and results related to the tests that have been conducted. To cope with vaccinations, antibody testing is being done in part for anti-nucleocapsid antibodies instead/next to anti-spike protein antibodies. Nevertheless, this does not change the basic rationale/approach of the antibody monitoring.

Table1. Intermediate Testing Report				
Infections Testing	Number	Positive results	Negative Results	Rejected Samples
Participants self reported tests	9881	343	9538	NA
Self reported PCR test (0)	8244	304	7940	NA
Self reported Antigen tests (1)	1314	29	1285	NA
Self reported Serology (2)	4	0	4	NA
Self reported unknown (3)	292	8	284	NA
Self reported other (88)	27	2	25	NA
Participants self tests sent	718			
Participants self tests received	539	0	539	0
Serology Testing				
Baseline samples tested	2221 (S)/1171 (N)*			
Learning phase samples tested	10597 (S)/6326(N)*	753(non-vacc) and 207(vacc) of which 580 and 86 were seroconversions respectively		328 samples (BL+LP) were rejected for analysis due to insufficient blood volume

* No. of tests. Part of the samples have been tested for both N and S.